Product Information
TREXALL 10 MG TABLET is a brand (anda) product labeled by Teva Women's Health, Inc., priced at $48.1352 per EA under NDC 51285036801. Its NADAC has been published 94 times since Dec 18, 2024.
FDA first approved this application on Mar 21, 2001.
The High Outlier badge above means this manufacturer's average price in the Methotrexate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
10 mg/1
Manufacturer
Teva Women's Health, Inc.NDC
51285036801
Classification
Brand (ANDA)
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
METHOTREXATE SODIUMApproval Type
Generic (ANDA)
FDA Application
ANDA040385FDA Approved
3/21/2001
On Market Since
5/3/2001
Pharmacological Classes
Price Statistics
The NADAC for TREXALL 10 MG TABLET has been published 94 times since Dec 18, 2024, and over the history we have for it it has risen 18.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $48.1352 per EA |
|---|---|
| All-time high | $48.4836 (May 13, 2026) |
| All-time low | $40.5098 (Dec 18, 2024) |
| 52-week high | $48.4836 |
| 52-week low | $44.3177 |
| Median price | $44.3177 |
| Average price | $45.8681 |
| Largest weekly change | +9.4% (Jan 7, 2026) |
| Weeks tracked | 94 |
| Tracking since | Dec 18, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Methotrexate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Women's Health, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Methotrexate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Folate Analog Metabolic Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TREXALL 10 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TREXALL 10 MG TABLET, manufactured by Teva Women's Health, Inc., is $48.1352 per EA (NDC 51285036801), effective Sep 30, 2026.
How has the price of TREXALL 10 MG TABLET changed over time?
Over the history we have for it, the NADAC for TREXALL 10 MG TABLET has risen 18.8%. It has been tracked across 94 weekly CMS publications since Dec 18, 2024.
What are the highest and lowest recorded NADAC prices for TREXALL 10 MG TABLET?
Since Dec 18, 2024, the NADAC for TREXALL 10 MG TABLET has ranged from a low of $40.5098 (Dec 18, 2024) to a high of $48.4836 (May 13, 2026), with a median of $44.3177 per EA.
Are there cheaper alternatives to TREXALL 10 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of TREXALL 10 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures TREXALL 10 MG TABLET?
TREXALL 10 MG TABLET (NDC 51285036801) is labeled by Teva Women's Health, Inc., and CMS classifies it as a brand (anda) product.